August 8, 2023, Vol 330, No. 6, Pages 487-574

This Week in JAMA

Audio Highlights

Abstract Full Text

free access online only has audio

JAMA. 2023;330(6):e2216007. doi:10.1001/jama.2022.16007

Audio: Donanemab for Alzheimer Disease, Sugary Drinks and Liver Disease, Cervical Cancer Screening, and more

Original Investigation

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

John R. Sims, MD; Jennifer A. Zimmer, MD; Cynthia D. Evans, PhD; et al.

Abstract Full Text

free access has audio

JAMA. 2023;330(6):512-527. doi:10.1001/jama.2023.13239

This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody designed to clear brain amyloid plaque, among patients with early symptomatic Alzheimer disease.

Podcast: Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease

Editorial
Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?
Jennifer J. Manly, PhD; Kacie D. Deters, PhD

JAMA
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
Gil D. Rabinovici, MD; Renaud La Joie, PhD

JAMA
- Podcast: Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease
Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy
Meredith B. Rosenthal, PhD

JAMA
Ushering in a New Era of Alzheimer Disease Therapy
Eric W. Widera, MD; Sharon A. Brangman, MD; Nathaniel A. Chin, MD

JAMA

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial

Tomas G. Neilan, MD, MPH; Thiago Quinaglia, MD, PhD; Takeshi Onoue, MD; et al.

Abstract Full Text

free access has active quiz has audio

JAMA. 2023;330(6):528-536. doi:10.1001/jama.2023.11887

This randomized trial assesses the effect of 12 months of atorvastatin vs placebo on development of cardiac dysfunction among patients with lymphoma undergoing anthracycline-based chemotherapy.

Audio: Atorvastatin to Reduce Risk of Anthracycline-Associated Cardiac Dysfunction

Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Liver Cancer and Chronic Liver Disease Mortality

Longgang Zhao, PhD; Xinyuan Zhang, PhD; Mace Coday, PhD; et al.

Abstract Full Text

free access

JAMA. 2023;330(6):537-546. doi:10.1001/jama.2023.12618

This observational study evaluated incidence of liver cancer and death from chronic liver disease among postmenopausal women by comparing intake of 3 or fewer servings of sugar-sweetened beverages per month vs intake of 1 or more sugar-sweetened beverages per day.

Research Letter

Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes

Brian E. McGarry, PT, PhD; Benjamin D. Sommers, MD, PhD; Andrew D. Wilcock, PhD; et al.

Abstract Full Text

free access

JAMA. 2023;330(6):561-563. doi:10.1001/jama.2023.12945

This study examines the use of COVID-19 antiviral treatments in US nursing homes and the facility characteristics associated with use of oral antivirals and monoclonal antibodies.

Viewpoint

Promoting Data Harmonization of COVID-19 Research in Pregnant and Pediatric Populations

Jessica L. Gleason, PhD, MPH; Robert Tamburro, MD, MSc; Caroline Signore, MD, MPH

Abstract Full Text

JAMA. 2023;330(6):497-498. doi:10.1001/jama.2023.10835

This Viewpoint investigates the use of common data elements to promote data harmonization in COVID-19–related studies of pediatric and pregnant populations.

Providing Responsible Health Care for Out-of-State Patients

Carmel Shachar, JD, MPH; Barak D. Richman, JD, PhD; Ateev Mehrotra, MD

Abstract Full Text

JAMA. 2023;330(6):499-500. doi:10.1001/jama.2023.10411

This Viewpoint discusses why the legality of calling patients located in another state has suddenly been called into question.

A Piece of My Mind

Escaping the Siren Song—Transitioning to Part-Time Work

Ariela L. Marshall, MD

Abstract Full Text

JAMA. 2023;330(6):501-502. doi:10.1001/jama.2023.13214

In this narrative medicine essay, a hematologist redirects her long-embraced ideal career as an academic physician for a more balanced life and for the work she loves in a part-time position.

Editorial

Ushering in a New Era of Alzheimer Disease Therapy

Eric W. Widera, MD; Sharon A. Brangman, MD; Nathaniel A. Chin, MD

Abstract Full Text

JAMA. 2023;330(6):503-504. doi:10.1001/jama.2023.11701

Editorial
Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?
Jennifer J. Manly, PhD; Kacie D. Deters, PhD

JAMA
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
Gil D. Rabinovici, MD; Renaud La Joie, PhD

JAMA
- Podcast: Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease
Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy
Meredith B. Rosenthal, PhD

JAMA

Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy

Meredith B. Rosenthal, PhD

Abstract Full Text

JAMA. 2023;330(6):505-506. doi:10.1001/jama.2023.11702

Editorial
Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?
Jennifer J. Manly, PhD; Kacie D. Deters, PhD

JAMA
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
Gil D. Rabinovici, MD; Renaud La Joie, PhD

JAMA
- Podcast: Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease
Ushering in a New Era of Alzheimer Disease Therapy
Eric W. Widera, MD; Sharon A. Brangman, MD; Nathaniel A. Chin, MD

JAMA

Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease

Gil D. Rabinovici, MD; Renaud La Joie, PhD

Abstract Full Text

has audio

JAMA. 2023;330(6):507-509. doi:10.1001/jama.2023.11703

Podcast: Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease

Editorial
Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?
Jennifer J. Manly, PhD; Kacie D. Deters, PhD

JAMA
Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy
Meredith B. Rosenthal, PhD

JAMA
Ushering in a New Era of Alzheimer Disease Therapy
Eric W. Widera, MD; Sharon A. Brangman, MD; Nathaniel A. Chin, MD

JAMA

Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?

Jennifer J. Manly, PhD; Kacie D. Deters, PhD

Abstract Full Text

JAMA. 2023;330(6):510-511. doi:10.1001/jama.2023.11704

Editorial
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
Gil D. Rabinovici, MD; Renaud La Joie, PhD

JAMA
- Podcast: Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease
Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy
Meredith B. Rosenthal, PhD

JAMA
Ushering in a New Era of Alzheimer Disease Therapy
Eric W. Widera, MD; Sharon A. Brangman, MD; Nathaniel A. Chin, MD

JAMA

Review

Cervical Cancer Screening: A Review

Rebecca B. Perkins, MD, MSc; Nicolas Wentzensen, MD, PhD, MS; Richard S. Guido, MD; et al.

Abstract Full Text

has active quiz has audio

JAMA. 2023;330(6):547-558. doi:10.1001/jama.2023.13174

This narrative review summarizes current evidence on HPV pathophysiology and cervical cancer prevention.

Podcast: Cervical Cancer: The Importance of HPV Testing and Vaccination

JAMA Clinical Guidelines Synopsis

Diagnosis and Management of Priapism

Richard J. Fantus, MD; Robert E. Brannigan, MD; Andrew M. Davis, MD, MPH

Abstract Full Text

has active quiz

JAMA. 2023;330(6):559-560. doi:10.1001/jama.2023.13377

This JAMA Clinical Guidelines Synopsis summarizes the 2022 American Urological Association/Sexual Medicine Society of North America guidelines on diagnosis and management of priapism.

Editor's Note

Losing the Human Voice

Rafael Campo, MD, MA

Abstract Full Text

free access

JAMA. 2023;330(6):568. doi:10.1001/jama.2023.13002

Medical News & Perspectives

Mounting Evidence Suggests That BMI Isn’t the Only Measure Needed to Predict Mortality Risk

Kate Ruder, MSJ

Abstract Full Text

JAMA. 2023;330(6):490-491. doi:10.1001/jama.2023.13602

This Medical News article discusses the association of body mass index categories with the risk of mortality from all causes.

How the SCOTUS Affirmative Action Ruling Could Affect Medical Schools and Health Care

Rita Rubin, MA

Abstract Full Text

JAMA. 2023;330(6):492-494. doi:10.1001/jama.2023.13603

This Medical News feature examines the potential impact of the US Supreme Court’s affirmative action decision on medical schools and health care.

Medical News in Brief

Alzheimer Drug Lecanemab Gains Traditional FDA Approval

Emily Harris

Abstract Full Text

JAMA. 2023;330(6):495. doi:10.1001/jama.2023.12548

First Ever Malaria Vaccine to Be Distributed in Africa

Emily Harris

Abstract Full Text

JAMA. 2023;330(6):495. doi:10.1001/jama.2023.12549

Shortened TB Regimen Not Effective

Emily Harris

Abstract Full Text

JAMA. 2023;330(6):495. doi:10.1001/jama.2023.12550

Few In-Network Psychiatrists Under Medicare Advantage

Emily Harris

Abstract Full Text

JAMA. 2023;330(6):495. doi:10.1001/jama.2023.12551

Water and Sanitation Crisis Affects Women and Girls Most

Emily Harris

Abstract Full Text

JAMA. 2023;330(6):495-496. doi:10.1001/jama.2023.12552

Study Tests Large Language Models’ Ability to Answer Clinical Questions

Emily Harris

Abstract Full Text

JAMA. 2023;330(6):496. doi:10.1001/jama.2023.12553

Medical Cannabis Did Not Reduce Pain Prescriptions, Procedures

Emily Harris

Abstract Full Text

JAMA. 2023;330(6):496. doi:10.1001/jama.2023.12554

Study Helps Explain Racial Disparities in Biological Aging

Emily Harris

Abstract Full Text

JAMA. 2023;330(6):496. doi:10.1001/jama.2023.12555

Schizophrenia Linked With Genetic Changes That Are Not Inherited

Emily Harris

Abstract Full Text

JAMA. 2023;330(6):496. doi:10.1001/jama.2023.12556

Poetry and Medicine

Anthropophagia

Benjamin Crawford, MA

Abstract Full Text

JAMA. 2023;330(6):568. doi:10.1001/jama.2023.11636

Editor's Note
Losing the Human Voice
Rafael Campo, MD, MA

JAMA

JAMA Revisited

The Occurrence of Arsenic in the Body

Abstract Full Text

JAMA. 2023;330(6):569. doi:10.1001/jama.2022.16008

JAMA Patient Page

What Is Acute Myocarditis?

Kristin Walter, MD, MS

Abstract Full Text

free access

JAMA. 2023;330(6):574. doi:10.1001/jama.2023.5526

This JAMA Patient Page describes acute myocarditis and its symptoms, causes, diagnosis, and treatment.

Comment & Response

Review of Prediabetes

Taher Entezari-Maleki, PharmD

Abstract Full Text

JAMA. 2023;330(6):563-564. doi:10.1001/jama.2023.9956

Review of Prediabetes

Mayer B. Davidson, MD

Abstract Full Text

JAMA. 2023;330(6):564. doi:10.1001/jama.2023.9959

Review of Prediabetes—Reply

Sam Dagogo-Jack, MD, DSc

Abstract Full Text

JAMA. 2023;330(6):564-565. doi:10.1001/jama.2023.9964

Implications of Nonhuman “Authors”

Chika Edward Uzoigwe, MA

Abstract Full Text

JAMA. 2023;330(6):565-566. doi:10.1001/jama.2023.10571

Editorial
Nonhuman “Authors” and Implications for the Integrity of Scientific Publication and Medical Knowledge
Annette Flanagin, RN, MA; Kirsten Bibbins-Domingo, PhD, MD, MAS; Michael Berkwits, MD, MSCE; Stacy L. Christiansen, MA

JAMA

Implications of Nonhuman “Authors”

Kentaro Matsui, MD, PhD; Masahide Koda, MD, PhD; Kazunari Yoshida, MD, PhD

Abstract Full Text

JAMA. 2023;330(6):566. doi:10.1001/jama.2023.10568

Editorial
Nonhuman “Authors” and Implications for the Integrity of Scientific Publication and Medical Knowledge
Annette Flanagin, RN, MA; Kirsten Bibbins-Domingo, PhD, MD, MAS; Michael Berkwits, MD, MSCE; Stacy L. Christiansen, MA

JAMA

Implications of Nonhuman “Authors”—Reply

Annette Flanagin, RN, MA; Kirsten Bibbins-Domingo, PhD, MD, MAS

Abstract Full Text

JAMA. 2023;330(6):566-567. doi:10.1001/jama.2023.10574

Editorial
Nonhuman “Authors” and Implications for the Integrity of Scientific Publication and Medical Knowledge
Annette Flanagin, RN, MA; Kirsten Bibbins-Domingo, PhD, MD, MAS; Michael Berkwits, MD, MSCE; Stacy L. Christiansen, MA

JAMA

Correction

Error in Author Surname

Abstract Full Text

free access

JAMA. 2023;330(6):567. doi:10.1001/jama.2023.13906

September 2024 - July 1883

Decade

Year

Issue

August 8, 2023, Vol 330, No. 6, Pages 487-574

Latest from the USPSTF